XORTX Therapeutics Inc.’s Post

🧠 Monoclonal antibody drugs are the first disease modifying #drugs for #Alzheimers. Our interactive guide explains in depth what #mabdrugs are, their FDA-approved options, and the relationship between mab drugs and the risk of brain bleeds in patients. 💊 Understanding these drugs is crucial for patients, #caregivers, and healthcare professionals. 🔗 Learn more: https://buff.ly/3SRwygP 🔗

This article, published in the latest European Biopharmaceutical Review issue, provides great insights from Ivo Timmermans and Dan Gelvan on maximising the opportunities and navigating the challenges of developing a first-in-class therapy. #PlecoTherapeutics #Firstinclass #Healthcareinnovation #EBRMagazine

Sgl2 induced eDka DRUG INTERACTIONS 60yr female patients diagnosed with ca pancreas, the patient evaluated for disease status ,she underwent PET CET which showed carcinoma of pancreas , patient planned for chemotherapy with INJ. FOLFIRI regimen for 6 cycle and then reassessment , patient having comorbidities DM2 and taking tab. oxaramet ( dapagliflozin ) after that patient experienced Dka #clinicalpharmacy# drug interactions # adverse drug reactions

CUV901, the first study in our Parkinson’s Disease program, is evaluating the safety and clinical effects of afamelanotide in six fair-skinned patients with early-stage disease, the first time a targeted MC1R therapy is being used in Parkinson’s patients.   #parkinsons #MC1R #melanocortins #peptides #skinandbrain

Vertex to buy kidney disease drugmaker Alpine for $4.9B https://lnkd.in/gwueavba Vertex Pharmaceuticals on Wednesday said it would buy biotechnology company Alpine Immune Sciences and its experimental kidney disease drug for $65 per share, or approximately $4.9 billion in cash. Through the deal, which the companies expect to close in the second quarter, Vertex will gain access to povetacicept, a therapy for IgA nephropathy, or IgAN. The drug is set to enter Phase 3 testing by the end of the year. The acquisition is the largest in Vertex’s 35-year history and comes as the company works to expand into kidney disease treatment. Vertex has for years sought ways to branch out beyond its highly successful cystic fibrosis medicines, which have catapulted it into the top ranks of the biotech industry. That strategy has led it in several different directions, among them pain , sickle cell disease , Type 1 diabetes and a rare lung disease known… Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

SGLT2 inhibitors have shown superior effectiveness in promoting regression of metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with type 2 diabetes, compared to other oral antidiabetic drugs. This research highlights their potential to not only improve liver health but also reduce adverse liver outcomes, suggesting SGLT2 inhibitors as a promising option for treating MASLD in diabetic patients. “Sodium-glucose cotransporter 2 inhibitors were associated with a higher likelihood of disease regression among patients with concomitant metabolic dysfunction-associated steatotic liver disease and type 2 diabetes, data showed.” “Obesity and insulin resistance are shared risk factors between MASLD and type 2 diabetes, and MASLD affects 55.5% of those who have been diagnosed with type 2 diabetes.” “SGLT2 inhibitors were distinguished by their association with fatty liver improvement, surpassing other [oral antidiabetic drugs] known for their potential benefits in MASLD,” Won Kim, MD, PhD said.” Kate Burba, thank you for writing this paper summary from Jang H, et al. JAMA Intern Med. 2024;https://lnkd.in/gMnAWFTf.

Science has no limits! Turning the kidney from a victim to a therapeutic target! I was lucky to be part of the incredible team that worked on SGLT2 inhibition awareness at the early beginning and I can recall the challenges we faced to change the perception/mindset and convince the scientific community that the kidney could be a target to control diabetes rather than a victim to diabetes! Now, I'm thrilled to see that SGLT2 inhibitors are essential treatments to: - control T2D - reduce CV events for patients with T2D - reduce risk of hospitalization and death for patients with HF - reduce the e-GFR decline in patients with CKD Moreover, they are potential treatments for obesity and MASLD! #sciencewins #SGLT2inhibitors

🌍 This #RareDiseaseDay, we're shining a light on the power of innovation. Sutura Therapeutics' drug conjugates platform is breaking barriers in rare disease treatment, offering new hope where it's needed most. #SuturaInnovation #HopeInEveryMolecule #SuturaTech #InCellTherapy #BiotechInnovation

Did you know that S1P receptor modulators have been helping patients manage multiple sclerosis for nearly a decade? These oral medications target specific receptors to regulate immune responses and reduce inflammation, making them a promising treatment for conditions like ulcerative colitis. In our latest series, Dr. Laura Targownik dives into the benefits and risks of S1P receptor modulators. Click here to learn more: https://lnkd.in/e-u6yejB Pfizer #UlcerativeColitis

September is National Sickle Cell Awareness Month, dedicated to increasing understanding and awareness of sickle cell disease (SCD), a genetic blood disorder that can lead to severe pain and serious health complications. This month, we focus on raising awareness about the condition, its symptoms, and the importance of early detection. Major companies like Global Blood Therapeutics, Pfizer, Agios Pharmaceuticals, Editas Medicine, Forma Therapeutics, Novo Nordisk, Bausch Health Companies Inc., bluebird bio, and others are at the forefront of developing innovative therapies, including #Voxelotor and #Crizanlizumab, aimed at improving the quality of life for those affected by SCD. Let’s join together to spread the word, support ongoing research, and empower individuals to take charge of their health. Every action, no matter how small, can make a significant impact in the fight against sickle cell disease. Together, we can drive progress and make a meaningful difference! Explore Sickle Cell Disease market trends and forecasts until 2034!  https://lnkd.in/gi5RUF-X #SickleCellAwareness #FightSCD #EducationIsPower #SupportResearch #QualityOfLife #SickleCellDisease #HopeForHealing #TogetherForACure